Mukund Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mukund Mehta, Managing Director and Promoter of Kilitch Drugs (India) Limited, has filed an annual disclosure with BSE and NSE as required under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The declaration confirms that the promoters and persons acting in concert have not created any encumbrance (such as pledge, lien, or charge) on their shares during the financial year ended 31st March 2025. This is a routine yearly compliance filing mandated for promoter groups, and it was submitted on 5th April 2025.
This is a routine annual compliance filing with no material impact on the stock. The fact that no encumbrance was created on promoter holdings is mildly reassuring, as it suggests promoters have not needed to pledge their shares for borrowing, indicating financial stability.